Profound weight loss, rather than medication itself, appears to be the major mechanism for hair loss in people who have this ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

More Americans are turning to peptides for muscle building, skin rejuvenation, and to try and live longer even though the ...

Injectable weight-loss drugs such as Ozempic and Mounjaro may do more than help people shed pounds—they may also protect the ...

New research reveals that tirzepatide and semaglutide both offer strong, early heart-protective effects. A major new ...

The Metsera buyout brings multiple obesity and cardiometabolic drug candidates into Pfizer’s pipeline, including a GLP-1 ...

Americans are going to get a little healthier. President Trump cut deals with the drugmakers Eli Lilly and Novo Nordisk to increase access to obesity drugs in a major benefit to American public health ...

In a landmark approval, the U.S. Food and Drug Administration (FDA) has authorized Rybelsus , the first oral GLP-1 receptor ...

Some doctors in China want national insurance coverage for weight-loss drugs to tackle endemic obesity, medical professionals told Reuters in rare instances of public advocacy, halfway through a ...

Andy Richter opened up on his Dancing with the Stars weight loss, giving credit to GLP-1 medication, Zepbound, and the challenges behind using these drugs on Julianne Hough’s “The Morning After Show.” ...

Weight loss at the time of GLP-1 discontinuation was 10.1% overall, 9.7% for those with T2D, and 11.1% for those without.